These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 28443391)

  • 21. Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
    Yao AH; Moore CL; Lim PL; Molina JM; Madero JS; Kerr S; Mallon PW; Emery S; Cooper DA; Boyd MA;
    Antivir Ther; 2018; 23(1):21-32. PubMed ID: 28447585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
    Gantner P; Cuzin L; Allavena C; Cabie A; Pugliese P; Valantin MA; Bani-Sadr F; Joly V; Ferry T; Poizot-Martin I; Garraffo R; Peytavin G; Fafi-Kremer S; Rey D;
    HIV Med; 2017 Oct; 18(9):704-708. PubMed ID: 28444816
    [No Abstract]   [Full Text] [Related]  

  • 23. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
    Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
    J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents.
    Prasitsuebsai W; Sophonphan J; Chokephaibulkit K; Wongsawat J; Kanjanavanit S; Kosalaraksa P; Ngampiyakul C; Sangkla P; Hansudewechakul R; Kerr SJ; Puthanakit T; Ananworanich J;
    Pediatr Infect Dis J; 2017 Oct; 36(10):967-972. PubMed ID: 28520611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candidates for inclusion in a universal antiretroviral regimen: dolutegravir.
    Cahn P
    Curr Opin HIV AIDS; 2017 Jul; 12(4):318-323. PubMed ID: 28520610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agreement between Estimated and Measured Renal Function in an Everyday Clinical Outpatient Setting of Human Immunodeficiency Virus-Infected Individuals.
    Ahlström MG; Kjær A; Gerstoft J; Obel N
    Nephron; 2017; 136(4):318-327. PubMed ID: 28472812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    Margot NA; Wong P; Kulkarni R; White K; Porter D; Abram ME; Callebaut C; Miller MD
    J Infect Dis; 2017 Mar; 215(6):920-927. PubMed ID: 28453836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial.
    Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Rivas-Jeremías I; Espinosa N; Trujillo-Rodríguez M; Fernandez-Magdaleno T; Viciana P; López-Cortés LF
    Clin Infect Dis; 2017 Aug; 65(4):551-556. PubMed ID: 28449051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
    Boucquemont J; Lawson-Ayayi S; Rigothier C; Bonnet F; Proust-Lima C; Neau D; Greib C; Miremont-Salamé G; Dabis F; Dupon M; Dauchy FA;
    Nephron; 2017; 136(3):211-220. PubMed ID: 28445881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current drugs for HIV-1: from challenges to potential in HIV/AIDS.
    Peng Y; Zong Y; Wang D; Chen J; Chen ZS; Peng F; Liu Z
    Front Pharmacol; 2023; 14():1294966. PubMed ID: 37954841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis.
    Du P; Wang A; Ma Y; Li X
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30962262
    [No Abstract]   [Full Text] [Related]  

  • 34. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
    Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
    Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
    Crutchley RD; Guduru RC; Cheng AM
    HIV AIDS (Auckl); 2016; 8():47-65. PubMed ID: 27022304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
    Antunes F
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):569-576. PubMed ID: 28443391
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.